Erasca (ERAS) vs Edgewise Therapeutics (EWTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Erasca (ERAS) has outperformed Edgewise Therapeutics (EWTX) over the past year, gaining 469.4% versus a gain of 161.4%. Over five years, EWTX leads with a +123.1% price change compared with -20.7% for ERAS. Erasca is the larger company by market cap ($5.38 billion vs $4.27 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | EWTX |
|---|---|---|
| Share price | $15.39 | $39.31 |
| Market cap | $5.38B | $4.27B |
| 1-day change | +8.96% | -0.66% |
| YTD return | +279.57% | +59.46% |
| 1-year return | +469.35% | +161.36% |
| 5-year return | -20.67% | +123.06% |
| EPS (TTM) | $-0.95 | $-1.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-124.55M | $-167.79M |
| 52-week high | $24.28 | $48.51 |
| 52-week low | $2.11 | $14.25 |
| Distance from 52-week high | -36.64% | -18.97% |
| Analyst consensus | none | buy |
| Avg. price target upside | +56.71% | +33.86% |
| Average volume | 4.28M | 1.35M |
| Shares outstanding | 349.76M | 108.60M |
| Employees | 103 | 127 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed EWTX by 308.0 percentage points over the past year.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
ERAS vs EWTX FAQ
Which is bigger, Erasca or Edgewise Therapeutics?
Erasca (ERAS) is larger, with a market capitalization of $5.38B compared with $4.27B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, ERAS or EWTX?
ERAS returned +469.35% over the past 12 months, compared with +161.36% for EWTX (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and Edgewise Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.